September 30, 2008 - GE Healthcare (GE) has acquired MicroCal LLC, a provider of instruments for the study of molecular interactions in pharmaceutical, biomedical and life science research, as GE moves to expand its offering for protein science and drug discovery research.
MicroCal develops and manufactures microcalorimeters that provide detailed information on the structure, function and binding properties of a wide range of biomolecules such as proteins, lipids, nucleic acids and antibodies. The growing trend towards structure-based drug design together with the expansion in biopharmaceutical development is driving an increase in the use of microcalorimetry as a standard technique in pharmaceutical research.
MicroCal’s proprietary technology, which is complementary to GE Healthcare’s Biacore platform, provides scientists with detailed information across several stages of the drug discovery process, reducing the potential for late-stage drug candidate failures. MicroCal’s technology is already used in over one thousand laboratories worldwide.
Peter Ehrenheim, president and CEO of GE Healthcare’s Life Sciences business, said, “MicroCal is a company with a strong reputation for innovation in microcalorimetry and is a great strategic fit with our Life Sciences business. The combination of GE Healthcare’s expertise in protein science together with the talent of the team at MicroCal will help us drive development of new technologies and create an extensive offering across the full spectrum of the drug discovery and development process.”
GE Healthcare plans to develop the MicroCal facility in Northampton, MA into a center of excellence for microcalorimetry. This acquisition is consistent with GE's strategy to invest in high-technology, innovative businesses that deliver strong top-line growth and expanded margins.
"We are very excited to be part of GE Healthcare,” said Richard Brown, CEO, MicroCal. "We see great potential for this business. The resources of GE Healthcare and the wider GE group will allow us to significantly widen our reach and to jointly develop new technologies, products and applications which will help scientists increase their understanding of molecular interactions. The MicroCal team very much looks forward to working with GE Healthcare’s leadership to realize the potential of this great technology.”
For more information: www.gehealthcare.com
May 01, 2024 
![(A) PET images of [68Ga]Ga-DOTA-ZCAM241 uptake at baseline and 3, 7, and 12 days after injection as inflammatory arthritis developed in single representative individual mouse. Images are normalized to SUV of 0.5 for direct comparison between time points. (B) CD69 immunofluorescence Sytox (Thermo Fisher Scientific) staining of joints of representative animals during matching time points.](/sites/default/files/styles/feed_medium/public/PET%20Tracers.jpeg?itok=P5Di6MIe)
